Site icon pharmaceutical daily

Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders

Long-term data from Opdivo plus Yervoy-based combinations demonstrate durable survival in metastatic non-small cell lung cancer (NSCLC) and metastatic melanoma, including results from landmark five-year analysis of CheckMate -227 in NSCLC

First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm

New data from pivotal MEDALIST and BELIEVE studies of Reblozyl in myelodysplastic syndromes and beta thalassemia highlight long-term anemia control in serious myeloid diseases

Data from pivotal RELATIVITY -047 trial studying Opdualag reinforce efficacy of LAG-3 mechanism in advanced melanoma

PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #ASCO22Bristol Myers Squibb (NYSE: BMY) today announced the presentation of scientific research across cancers and blood disorders at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress that underscores the company’s commitment to delivering transformational therapies for patients. Data from more than 140 company-sponsored studies, investigator-sponsored studies and collaborations evaluating compounds across 28 cancer types and blood disorders will be featured at the two meetings.

“We have made significant progress for patients with cancer and blood disorders by delivering clinically meaningful and differentiated treatment choices across modalities such as CAR T, immunotherapy and erythroid maturation,” said Samit Hirawat, M.D., executive vice president, chief medical officer, Global Drug Development, Bristol Myers Squibb. “Driven by our deep understanding of human biology and leading scientific research, the results being presented at ASCO and EHA will provide greater insight into the potential for improving long-term outcomes, and rationale for moving innovative interventions into earlier lines of treatment. Beyond our data, we are focused on improving care for all patients through our Health Equity Commitments, aimed at increasing diversity in clinical trials, addressing health disparities, and investing in training for racially and ethnically diverse clinical investigators.”

Key data being presented by Bristol Myers Squibb at ASCO and EHA 2022 include:

Solid Tumor

Cell Therapy

Hematology

Early Assets

Summary of Presentations

Select Bristol Myers Squibb studies at the 2022 ASCO Annual Meeting include:

Abstract Title

Author

Presentation Type/#

Session Title

Session Date/ Time

Acute Myeloid Leukemia

Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML).

Courtney DiNardo

 

Poster

Abstract #7032

 

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Saturday, June 4, 2022: 9:00 AM – 12:00 PM EDT

Assessing eligibility for non-intensive chemotherapy (IC) randomized clinical trials (RCT) in patients (pts) with newly diagnosed (ND) AML from the Connect Myeloid Disease Registry.

Harry Erba

Poster

Abstract #7029

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Saturday, June 4, 2022: 9:00 AM – 12:00 PM EDT

Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial.

Stephane De Botton

Oral

Abstract #7005

 

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Tuesday, June 7, 2022: 10:45 AM – 1:45 PM EDT

Gastrointestinal

Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.

Ian Chau

Poster

Abstract

#4035

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Saturday, June 4, 2022: 9:00 AM – 12:00 PM EDT

Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.

Michael Overman

Poster

Abstract

#3510

Gastrointestinal Cancer—Colorectal and Anal

Saturday, June 4, 2022: 9:00 AM – 12:00 PM EDT

Genitourinary

Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER.

Cristina Suarez

 

Oral

Abstract

#4501

Genitourinary Cancer—Kidney and Bladder

 

Friday, June 3, 2022: 3:45 PM – 6:45 PM EDT

The relationship between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) in CheckMate (CM) 214.

David Cella

Oral

Abstract

#4502

Genitourinary Cancer—Kidney and Bladder

Friday, June 3, 2022: 3:45 PM – 6:45 PM EDT

Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.

Daniel Geynisman

Poster

Abstract

#4548

Genitourinary Cancer—Kidney and Bladder

Saturday, June 4, 2022: 2:15 PM – 5:15 PM EDT

Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N+I) or sunitinib (SUN) in the CheckMate 214 trial.

Lucia Carril-Ajuria

 

Poster

Abstract

#4538

Genitourinary Cancer—Kidney and Bladder

 

Saturday, June 4, 2022: 2:15 PM – 5:15 PM EDT

Results for patients with muscle-invasive bladder cancer (MIBC) in the CheckMate 274 trial.

Alfred Witjes

Poster

Abstract

#4585

Genitourinary Cancer—Kidney and Bladder

Saturday, June 4, 2022: 2:15 PM – 5:15 PM EDT

Melanoma

Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047.

Hussein A. Tawbi

 

Oral

Abstract

#9505

Melanoma/Skin Cancers

Sunday, June 5, 2022: 10:45 AM – 1:45 PM EDT

Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047).

Georgina V. Long

Oral

Abstract #360385

ASCO Plenary Series: Rapid Abstract Updates

 

Sunday, June 5, 2022: 5:30 PM – 7:00 PM EDT

Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.

F. Stephen Hodi

Poster

Abstract

#9522

Melanoma/Skin Cancers

 

Monday, June 6, 2022: 2:15 PM – 5:15 PM EDT

Outcomes in patients with resected stage IIIA melanoma treated with adjuvant nivolumab or monitored with observation: A real-world study.

Anna C. Pavlick

Online only

 

Online only

Online only

Multiple Myeloma

Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty.

Albert Oriol Rocafiguera

Poster

Abstract #8024

 

Hematologic Malignancies—Plasma Cell Dyscrasia

 

Saturday, June 4, 2022: 9:00 AM – 12:00 PM EDT

Characteristics of long-surviving patients with multiple myeloma: Over 12 years of follow-up in the Connect MM Registry.

Howard R. Terebelo

Poster

Abstract #8027

Hematologic Malignancies—Plasma Cell Dyscrasia

Saturday, June 4, 2022: 9:00 AM – 12:00 PM EDT

Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma (RRMM) patients treated with idecabtagene vicleucel (ide-cel; bb2121), an anti-BCMA CAR T cell therapy.

Julie Rytlewski

Poster

Abstract

#8021

Hematologic Malignancies—Plasma Cell Dyscrasia

Saturday, June 4, 2022: 5:30 PM – 7:00 PM EDT

 

Myelodysplastic Syndromes

Long-term utilization and benefit of luspatercept in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) from the MEDALIST trial.

Pierre Fenaux

Poster

Abstract #7056

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Saturday, June 4, 2022: 9:00 AM – 12:00 PM EDT

Real-world erythropoiesis-stimulating agent (ESA) treatment patterns and outcomes among U.S. patients with lower-risk myelodysplastic syndromes (LR-MDS).

Sudipto Mukherjee

Online only

N/A

Online only

Clinical outcomes and healthcare resource utilization (HCRU) in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) reinitiating erythropoiesis-stimulating agents (ESAs) following previous ESA treatment.

Guillermo Garcia-Manero

Online only

N/A

Online only

Lymphoma

Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study.

Alison Sehgal

Poster

Abstract

#7062

 

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Saturday, June 4, 2022: 9:00 AM – 12:00 PM EDT

 

Lisocabtagene maraleucel (liso-cel) as second-line (2L) treatment (tx) for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Patient-reported outcomes (PRO) from the phase 2 PILOT study.

Leo I. Gordon

 

Poster

Abstract #6567

 

Health Services Research and Quality Improvement

Monday, June 6, 2022: 2:15 PM – 5:15 PM EDT

 

Ovarian

Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): Results from the expansion part of a phase 1 trial.

Shin Nishio

Poster

Abstract

#5513

Gynecologic Cancer

Saturday, June 4, 2022: 5:30 PM – 7:00 PM EDT

Dose optimization for MORAb-202, an antibody-drug conjugate (ADC) highly selective for folate receptor-alpha (FRα), using population pharmacokinetic (PPK) and exposure-response (E-R) efficacy and safety analyses.

Seiichi Hayato

Poster

Abstract

#3090

Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology

Sunday, June 5, 2022; 9:00 AM – 12:00 PM EDT

Thoracic

Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227.

Julie R. Brahmer

Poster

Abstract

#LBA9025

Lung Cancer—Non-Small Cell Metastatic

Monday, June 6, 2022: 9:00 AM – 12:00 PM EDT

First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.

Luis G. Paz-Ares

Poster

Abstract

#LBA9026

Lung Cancer—Non-Small Cell Metastatic

Monday, June 6, 2022: 9:00 AM – 12:00 PM EDT

Association of early tumor growth rate and survival outcomes in first-line metastatic non–small cell lung cancer (mNSCLC).

Antonio Tito Fojo

Poster

Abstract

#9063

Lung Cancer—Non-Small Cell Metastatic

Monday, June 6, 2022: 9:00 AM – 12:00 PM EDT

Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816.

Mariano Provencio-Pulla

Poster

Abstract

#LBA8511

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Monday, June 6, 2022: 12:30 PM – 2:00 PM EDT

All abstracts except late-breaking abstracts will be available on the ASCO website at 5:00 PM EDT on Thursday, May 26. All late-breaking abstracts will be available on the ASCO website at 8:00 AM EDT on the day of the scientific session for the abstract presentation.

Select Bristol Myers Squibb studies at the 2022 EHA Congress include:

Abstract Title

Author

Presentation Type/#

Session Date/Time

Acute Myeloid Leukemia

Clinical and Biological Markers Associated With Long-term Survival for Patients With Acute Myeloid Leukemia (AML) in Remission After Chemotherapy in the QUAZAR AML-001 Trial of Oral Azacitidine

Andrew Wei

Poster

Abstract #P498

Friday, June 10, 2022:

12:30 – 1:45 PM EDT (6:30 – 7:45 PM CEST)

Real-World Efficacy Outcomes of Venetoclax Plus Azacitidine vs. Intensive Chemotherapy for Induction Therapy in Adult Patients with Acute Myeloid Leukemia

Amer Zeidan

Poster

Abstract #P570

 

Friday, June 10, 2022:

12:30 – 1:45 PM EDT (6:30 – 7:45 PM CEST)

Oral Azacitidine vs. Midostaurin as Maintenance Treatment for FLT3 Mutant Acute Myeloid Leukemia in Complete Remission: An Indirect Treatment Comparison

Esther Natalie Olivia

Poster

Abstract #P571

 

Friday, June 10, 2022:

12:30 – 1:45 PM EDT (6:30 – 7:45 PM CEST)

Beta thalassemia

Long-term Safety Results of the BELIEVE Study of Luspatercept in Adults with Beta-thalassemia

Vip Viprakasit

Poster

Abstract #P1518

Friday, June 10, 2022:

12:30 – 1:45 PM EDT (6:30 – 7:45 PM CEST)

Examining the Burden of Illness Associated With Transfusion-Dependent Βeta-Thalassemia From the Patient’s Perspective

Russell L. Knoth

Poster

Abstract #P1741

Friday, June 10, 2022: 12:30 – 1:45 PM EDT (6:30 – 7:45 PM CEST)

Systematic Literature Review of the Burden of Illness and Outcome Analyses of Patients with Non-transfusion Dependent Beta Thalassemia

Yesim Aydinok

 

Poster

Abstract #P1742

Friday, June 10, 2022:

12:30 – 1:45 PM EDT (6:30 – 7:45 PM CEST)

Longer-term Analysis of Efficacy of Luspatercept vs. Placebo in Patients with Transfusion-Dependent Beta-thalassemia Enrolled in the BELIEVE Study

Maria Domenica Cappellini

Oral

Abstract #S270

Saturday, June 11, 2022: 12:30 – 1:45 PM EDT (6:30 – 7:45 PM CEST)

Lymphoma

Accuracy of Predicting Long-Term Survival of Chimeric Antigen Receptor (CAR) T Cell Therapies in Large B-Cell Lymphoma (LBCL)

Elisabeth J.M Verburg-Baltussen

Poster

Abstract #P1744

 

Friday, June 10, 2022:

12:30 – 1:45 PM EDT (6:30 – 7:45 PM CEST)

Treatment Patterns and Real-World Outcomes in Patients (PT) with Large B-Cell Lymphoma (LBCL) who received Second-Line (2L) Therapy

Matthew A. Lunning

 

Poster

Abstract #P1204

 

Friday, June 10, 2022:

12:30 – 1:45 PM EDT (6:30 – 7:45 PM CEST)

Lisocabtagene Maraleucel (liso-cel) as Second-Line Therapy for R/R Large B-Cell Lymphoma (LBCL) in Patients not Intended for HSCT: Primary Analysis from the Phase 2 PILOT Study

Alison Sehgal

Oral

 

Abstract #S258

Saturday, June 11, 2022: 12:30 – 1:45 PM EDT (6:30 – 7:45 PM CEST)

Clinical Activity of CC-99282, a Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (PTS) With Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) – Results From a Phase 1, Open-Label Study

Jean-Marie Michot

Oral

Abstract #S216

Sunday, June 12, 2022:

12:30 PM – 1:45 PM

EDT (6:30 – 7:45 PM CEST)

 

First Clinical Study of the Anti-Signal Regulatory Protein-alpha (SIRPα) Antibody CC-95251 Combined With Rituximab in Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Paolo Strati

Oral

Abstract #S219

Sunday, June 12, 2022:

12:30 – 1:45 PM EDT (6:30 – 7:45 PM CEST)

Multiple Myeloma

Tumor Profiling of Idecabtagene Vicleucel (Ide-cel; bb2121) Patients in KarMMa Showed Comparable Responses in Existing Molecular High-risk Subsets and Preliminary Gene Signature of Durable Response

Nathan Martin

 

Poster

Abstract #P867

 

Friday, June 10,2022:

12:30 – 1:45 PM EDT (6:30 – 7:45 PM CEST)

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Idecabtagene Vicleucel vs. Belantamab Mafodotin: a Matching-Adjusted Indirect Comparison Study

Nina Shah

Poster

Abstract #P1740

Friday, June 10, 2022:

12:30 – 1:45 PM EDT (6:30 – 7:45 PM CEST)

Biomarker Analysis to Support Dose Optimization of Iberdomide as Monotherapy and in Combination with Standard of Care Treatments for Multiple Myeloma From a Phase 1/2 Trial

Michael Amatangelo

Poster

Abstract #P865

 

Friday, June 10, 2022:

12:30 – 1:45 PM EDT (6:30 – 7:45 PM CEST)

The EHA presentations will be available on demand on Monday, June 20.

Bristol Myers Squibb: Creating a Better Future for People with Cancer

Bristol Myers Squibb is inspired by a single vision — transforming patients’ lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine, and through innovative digital platforms, are turning data into insights that sharpen their focus. Deep scientific expertise, cutting-edge capabilities and discovery platforms enable the company to look at cancer from every angle. Cancer can have a relentless grasp on many parts of a patient’s life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis to survivorship. Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.

OPDIVO Indications

OPDIVO® (nivolumab), as a single agent, is indicated for the treatment of adult patients with unresectable or metastatic melanoma.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of adult patients with unresectable or metastatic melanoma.

OPDIVO® (nivolumab) is indicated for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

OPDIVO® (nivolumab), in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC).

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab) and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC).

OPDIVO® (nivolumab), in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or after 3 or more lines of systemic therapy that includes autologous HSCT. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Contacts

Bristol Myers Squibb
Media Inquiries:
media@bms.com

Investors:
investor.relations@bms.com

Read full story here

Exit mobile version